THE Therapeutic Goods Administration has confirmed it is working with sponsors of "certain inhaled or injected anaesthetic agents and sedative medicines" to update information about the potential risks of deficits in learning and behavioural development in children which may be associated with repeated or prolonged exposure to the products during late pregnancy or early childhood.
The concern applies to all items that block N-methyl-D-aspartate (NDMA) receptors or potentiate gamma-aminobutyric acid (GABA) activity.
A fact sheet for parents and carers has been published about the potential concern - CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Oct 18
